Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Person › Details

Sandra Horning (Roche (Group))

Horning, Sandra (Roche 201401–201912 CMO + Head Global Product Development joined 2009 RETIRED 12/19)


Organisation Organisation Roche (Group)
Products Product drug development
  Product 2 pharmaceutical

Genentech, Inc.. (8/19/19). "Press Release: Retirement of Dr. Sandra Horning & Appointment of Dr. Levi Garraway to Chief Medical Officer, Roche and Genentech". South San Francisco, CA.

Dr. Sandra Horning, Chief Medical Officer and Head of Global Product Development will retire on December 31, 2019. During her decade-long tenure with Roche and Genentech, Dr. Horning brought 15 new medicines to patients and tackled some of the world’s toughest diseases including cancer, multiple sclerosis, influenza and blindness. We thank her for her incredible contributions to medicine and to the employees at our company who have been inspired and motivated by her commitment to science and patients.

Dr. Levi Garraway, who was most recently Eli Lilly’s Senior Vice President, Oncology Research & Development and Lilly Research Laboratories Novel Target Research, will succeed Dr. Horning as Chief Medical Officer and Head of Global Product Development effective October 1, 2019 and will be based in South San Francisco.

Click here to download biographies and photos. [ SEE BELOW]

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit

Biographies | Sandra Horning & Levi Garraway

Sandra J. Horning, M.D., FACP, FASCO

Dr. Sandra Horning was appointed Chief Medical Officer and Head of Global Product Development for Roche and Genentech in January 2014. She leads employees in the Product Development organization across the globe, oversees all aspects of late stage clinical development, and co-chairs the Late Stage Portfolio Committee that invests in pivotal registrational trials. During her tenure, she has received recognition for her industry contributions and overseen the successful development of 15 new molecular entities and numerous line extensions in oncology, hematology, neuroscience, ophthalmology, immunology and infectious disease.

Dr. Horning joined Roche and Genentech in late 2009 as Senior Vice President, Global Head of Clinical Science / Oncology and Hematology in the Product Development organization. Prior to that, she served as a tenured professor, practicing oncologist and investigator, and held multiple leadership positions including Vice-Chair of the Department of Medicine at Stanford University, where she is an Emerita Professor of Medicine (Oncology and Blood and Bone Marrow Transplantation). Dr. Horning has authored more than 300 peer-reviewed journal articles, book chapters, reviews and editorials, and has served on the editorial boards of multiple peer-reviewed medical journals. She was named a Best Doctor in America consecutively from 1992 - 2008 and served as Chairman of the Eastern Cooperative Oncology Group lymphoma committee and 2005 - 2006 President of the American Society of Clinical Oncology.

Dr. Horning received Bachelor of Arts and Doctor of Medicine degrees at the University of Iowa and completed post-doctoral training in internal medicine at the University of Rochester and in medical oncology at Stanford University.

Levi Garraway, M.D., Ph.D.

Dr. Levi Garraway, M.D., Ph.D., was most recently Eli Lilly’s Senior Vice President, Oncology Research and Development & Lilly Research Laboratories Novel Target Research. He joined Eli Lilly in 2017 as Senior Vice President, Global Development and Medical Affairs for their Oncology division. Prior to that, Dr. Garraway was director of the Joint Center for Cancer Precision Medicine, which spanned Harvard teaching hospitals including the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, and the Broad Institute of MIT and Harvard. He was also co-leader of the Cancer Genetics Program at the Dana-Farber / Harvard Cancer Center. In 2010, Dr. Garraway co-founded Foundation Medicine, the world’s leading provider of tumor molecular information.

A Fellow of the American Association for Cancer Research (AACR), over the course of his career Dr. Garraway has served on the advisory boards of major cancer centers including Memorial Sloan Kettering and MD Anderson. He also served on several major National Institutes of Health (NIH) committees as well as the Blue Ribbon Panel for the Beau Biden Cancer Moonshot Initiative. Dr. Garraway was president of the American Society of Clinical Investigation from 2014 - 2015. He is the author of nearly 200 peer-reviewed scientific articles and has received many awards, including the Paul Marks Prize for Cancer Research, the Jane Cooke Wright Award from the AACR, the New Innovator Award from the NIH, and an Outstanding Investigator Award from the National Cancer Institute.

Dr. Garraway is a graduate of Harvard, where he earned his A.B., M.D., and his Ph.D. in Biological
Chemistry and Molecular Pharmacology.

Record changed: 2021-08-14


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Sandra Horning

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px

» top